BIO GREEN MED SOLUTION INC. 6% CNV PFD USD(BGMSP.US)

BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion | BNXTF Stock News

BioNxt Solutions Inc. has made significant progress in its cladribine oral thin film (ODF) program for Multiple Sclerosis, achieving over 40% improvement in bioavailability. The company is now preparing for human clinical studies, leveraging the established safety profile of cladribine. Additionally, BioNxt is expanding its strategy to include Myasthenia Gravis, a rare autoimmune disease, using the same drug and delivery technology. This approach aims to enhance patient adherence and simplify administration, with a focus on capital-efficient commercialization in the growing autoimmune market.

BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS) | BNXTF Stock News

BioNxt Solutions Inc. has reported final preclinical results from a pig study showing that its sublingual oral dissolvable film (ODF) formulation of cladribine for treating Multiple Sclerosis (MS) achieved approximately 40% higher systemic drug delivery compared to conventional oral tablets. This significant improvement in drug delivery efficiency supports the advancement of the ODF formulation into human pharmacokinetic studies. The study's results indicate potential for optimized dosing and reduced side effects, positioning BioNxt's technology as a promising alternative for patients with neurological conditions.

BIO GREEN MED SOLUTION INC. 6% CNV PFD USD | 10-Q: FY2025 Q3 Revenue: USD 81 K

BIO GREEN MED SOLUTION INC. 6% CNV PFD USD | 8-K: FY2025 Q3 Revenue: USD 81 K

CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD | 10-Q: FY2025 Q2 Revenue: USD 0